Search results
FDA sets review date for Merck's KEYTRUDA in mesothelioma treatment By Investing.com
Investing.com· 9 hours agoMerck & Co., Inc., a global healthcare leader, has announced that the U.S. Food and Drug...
Merck acquires EyeBio in up to $3B deal By Proactive Investors
Investing.com· 6 hours agoMerck & Co Inc (NYSE:MRK, ETR:6MK) announced it is acquiring Eyebio, a privately held...
Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy
FierceBiotech· 14 hours agoMerck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech. Merck will take on a pipeline of vision ...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co...
Benzinga· 18 hours agoMerck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum...
MRK stock rated a Sell by Societe Generale – Knox Daily
Knox Daily· 2 days agoMerck & Co Inc’s filing revealed that its 10% Owner Merck & Co., Inc. acquired Company’s shares for reported $492.14 ...
Is Merck & Co., Inc. (NYSE:MRK) the Best Dow Stock To Buy According to Hedge Funds?
Insider Monkey via Yahoo Finance· 4 days agoWe recently identified the best dow stocks according to hedge funds. Even though Merck & Co., Inc....
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 15 hours agoJeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects ...
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Benzinga via Yahoo Finance· 1 day agoEditor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead...
Merck to buy EyeBio in a deal that could valued at up to $3 billion
Morningstar· 15 hours agoMerck & Co. Inc. (MRK) announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal ...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
WSAU Wausau· 1 day ago(Reuters) -Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company...